RxDoctor Payments Data

Arthur Lu, MD

Ophthalmology · Westminster, CANPI 1659434546

Payments from drug & device makers

$2,402in general payments, 2019–2025

Across 41 payments — averaging $58.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$646
  • Sun Pharmaceutical Industries Inc.$570
  • Amgen$367
  • Alcon$209
  • Beaver-visitec International, Inc.$164
  • Carl Zeiss Meditec, Inc.$137
  • plus $309 from 4 others

What the payments were for

  • Food & beverage$2,402100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,402 in reported general payments places this provider in the 60th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$260,179
Medicare patients
886
Services billed
3,676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine1,953$1,320,648
MieboPerfluorohexyloctane/Pf1,000$760,347
Cyclosporine1,380$472,606
XiidraLifitegrast547$391,778
CequaCyclosporine394$242,936
LumiganBimatoprost350$96,036
VyzultaLatanoprostene Bunod251$86,930
CombiganBrimonidine Tartrate/Timolol140$37,259
ProlensaBromfenac Sodium107$35,154
ZyletTobramycin/Lotepred Etab108$34,094
RocklatanNetarsudil Mesylat/Latanoprost100$32,367
Alphagan PBrimonidine Tartrate108$30,270
SimbrinzaBrinzolamide/Brimonidine Tart139$27,266
AzoptBrinzolamide66$23,728
ZerviateCetirizine Hcl46$22,202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta$646$1,239,0561,798 claims
Sun Pharmaceutical Industries Inc.Cequa$570$242,936394 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$45$52,337159 claims
AlconSimbrinza, Azopt$209$50,994205 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Westminster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →